Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status approved
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII 53AH36668S
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infantile vomiting18.04.11.004; 07.01.07.0100.000246%Not Available
Sinus node dysfunction02.03.03.0170.000168%
Device related thrombosis24.01.01.027; 08.07.05.0010.000112%Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.000381%Not Available
Bronchial carcinoma16.19.02.004; 22.08.01.0150.000470%Not Available
Lung adenocarcinoma16.19.01.002; 22.08.01.0070.001903%Not Available
Lung adenocarcinoma stage IV22.08.01.017; 16.19.01.0070.000168%Not Available
Lung carcinoma cell type unspecified stage IV22.08.01.019; 16.19.02.0060.000246%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000168%Not Available
Neuroblastoma16.30.03.002; 05.01.04.001; 17.20.03.0020.000302%Not Available
Non-small cell lung cancer stage IV22.08.01.022; 16.19.01.0100.000526%Not Available
Normal pressure hydrocephalus17.07.01.0020.000112%Not Available
Rectal perforation07.04.01.0040.000112%
Renal haematoma24.07.07.004; 20.01.02.018; 12.01.05.0060.000112%Not Available
Subclavian vein thrombosis24.01.02.0130.000112%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000112%Not Available
Necrotising oesophagitis07.04.05.0060.000112%Not Available
Biliary dilatation09.02.03.0040.000112%Not Available
Cell death14.11.02.005; 08.03.03.0030.000168%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.000112%Not Available
Gastrointestinal oedema07.11.01.0120.000224%Not Available
Gastrointestinal amyloidosis10.02.05.004; 07.11.01.0240.000168%Not Available
Non-small cell lung cancer metastatic22.08.01.021; 16.19.01.0090.000851%Not Available
Renal cyst haemorrhage24.07.07.003; 20.01.04.017; 16.27.01.0050.000112%Not Available
Embolic cerebral infarction24.01.04.009; 17.08.01.0290.000112%Not Available
Diffuse alveolar damage22.01.01.0190.000168%Not Available
Hypercreatininaemia20.01.02.016; 14.11.01.0390.000112%Not Available
Age-related macular degeneration06.09.03.0180.000112%Not Available
Inflammatory myofibroblastic tumour16.33.08.001; 15.09.02.0030.000112%Not Available
Protein deficiency14.03.02.0230.000112%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene